Novo Nordisk to slash prices of weightloss drugs in US / Photo: SCOTT OLSON - GETTY IMAGES NORTH AMERICA/AFP/File
-
Araujo says too soon to talk about permanent Liverpool move
-
Eagles star Hurts to miss rest of NFL season: reports
-
US wants to be 'strong partner' for central Asia: Rubio
-
Oil-rich Alberta votes on Canada breakup
-
'Special' to face friend Perez in Champions League, says Liverpool's Iraola
-
Israel announces arrests after West Bank settler attacks on Westerners
-
Monitor says Indonesia fires have burned nearly two million hectares
-
Guehi insists players have 'trust and belief' in Man City after charges
-
French PM says could declare state of emergency over unrest 'if needed'
-
UN climate panel head wants swift end to deadlock over key scientific report
-
Albanian PM warns of 'red line' after days of unrest
-
PM calls for curfews in France as govt grapples with unrest
-
Putin, Xi and Trump could meet at APEC summit: Kremlin
-
Man City's Semenyo out for up to eight weeks
-
Microsoft exits data centre deal in blow to UK AI ambitions
-
Australian lawmaker critically hurt in 'violent' vehicle attack
-
European stocks retreat as France violence spreads
-
England women's coach Wiegman signs two-year contract extension
-
North Korea warns 'grave situation' prevailing along border
-
Louvre blocked as France grapples with unrest
-
Raya proud of Arsenal's 'incredible' reaction after third straight win
-
Bollywood actor Tiger Shroff shot at in Mumbai, three suspects held: police
-
Indonesia fires have burned nearly two million hectares: monitor
-
UN biodiversity summit opens with nature goals off track
-
Australian lawmaker 'critically' hurt in attack, officials say
-
'Physical hell': Hong Kong hosts gruelling underwater hockey tournament
-
Indonesia fires burned over 1.9 mn hectares through September: monitor
-
Police 'lost control' during French protests, says interior minister
-
Asian tech stocks mixed after Wall St losses, eyes on earnings
-
Australia's new Ghost Shark submarines grow some 'teeth'
-
China's third-quarter growth narrowly beats forecasts
-
'I call it a bribe': Pennsylvania residents spurn $10,000 data center checks
-
Asian stocks start week on back foot, tracking tech-led Wall St losses
-
In a former US steel city, ordinary people struggle to get by
-
China growth narrowly beats forecasts
-
'Liar,' 'clown': Lula and Bolsonaro spar in Brazil poll debate
-
Faith and fury: Texas Senate rivals offer contrasting visions
-
Record El Nino? Depends who's counting
-
Women await justice for police killings in Brazil
-
On the front line of ocean conservation off Portugal's Madeira
-
The painstaking task of cataloguing the world's species
-
Wembanyama targets title breakthrough as NBA season tips off
-
Nations seek reset at UN talks as nature goals off track
-
With LeBron on board it's title or bust for Philly fans
-
Rubio seeks to strengthen US foothold in Central Asia
-
One year after Louvre heist, where are the missing jewels?
-
LeBron joins 76ers to chase one more NBA title at age 41
-
Knicks face tall task in NBA championship repeat bid
-
Rays one win from World Series return after downing Guardians
-
Warriors' Curry 'fine' after limping out of practice - Kerr
Novo Nordisk to slash prices of weightloss drugs in US
Danish drugmaker Novo Nordisk, which is struggling with competition for its anti-obesity treatments, said Tuesday that it will sharply cut prices for its flagship drugs in the US, announcing a 50 percent cut for Wegovy and 35 percent for Ozempic.
"This decision applies to all doses of these medicines and reflects Novo Nordisk's commitment to enhancing affordability for patients and both public and private payers dealing with the complexities of the evolving US healthcare system," the company said in a statement.
Effective January 1, 2027, the list price will be $675 for a month's worth of Wegovy, which currently costs around $1,350 a month.
Ozempic and Rybelsus, treatments that each currently come to about $1,000, will also be priced $675.
Novo Nordisk said the price reduction is meant to make it possible to reach more patients.
"Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States," Jamey Millar, executive vice president of Novo Nordisk's US Operations, said.
In early February, Novo Nordisk vowed legal against US chain Hims & Hers for offering a copycat of the new pill version of Wegovy.
Limited production capacity for the blockbuster drug led the FDA to temporarily allow pharmacies to create so-called "compound" or copycat versions of Wegovy and Ozempic, an analogue used to treat diabetes.
That authorisation expired last May 22 but Novo Nordisk has complained of copycat versions of its drugs still being available.
Ozempic is an injectable anti-diabetic treatment that became popular on social media for its slimming properties.
Wegovy, which has the same active ingredient as Ozempic in a different dose, is a weight-loss drug and is also available in pill form.
Both treatments use analogues of the hormone GLP-1, which regulates blood glucose levels and appetite.
Shares in Novo Nordisk have taken a beating in recent weeks after it warned in early February of lower sales revenue in the United States as intensified competition pushes down prices.
They fell 3.8 percent in afternoon trading in Copenhagen.
T.Perez--AT